194 related articles for article (PubMed ID: 16217026)
1. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity.
Leung TH; Ching YP; Yam JW; Wong CM; Yau TO; Jin DY; Ng IO
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15207-12. PubMed ID: 16217026
[TBL] [Abstract][Full Text] [Related]
2. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
[TBL] [Abstract][Full Text] [Related]
3. The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory stimuli.
Chan FK; Chung SS; Ng IO; Chung SK
Neurosignals; 2012; 20(2):112-26. PubMed ID: 22204965
[TBL] [Abstract][Full Text] [Related]
4. Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma.
Xiaorong L; Wei W; Liyuan Q; Kaiyan Y
BMC Cancer; 2008 Jul; 8():205. PubMed ID: 18651974
[TBL] [Abstract][Full Text] [Related]
5. DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration.
Lin Y; Chen NT; Shih YP; Liao YC; Xue L; Lo SH
Oncogene; 2010 May; 29(20):3010-6. PubMed ID: 20208559
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific roles of the GTPase activating protein Nadrin in cytoskeletal reorganization of platelets.
Beck S; Fotinos A; Lang F; Gawaz M; Elvers M
Cell Signal; 2013 Jan; 25(1):236-46. PubMed ID: 22975681
[TBL] [Abstract][Full Text] [Related]
7. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.
Sabbir MG; Prieditis H; Ravinsky E; Mowat MR
PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269
[TBL] [Abstract][Full Text] [Related]
8. Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway.
Leung TH; Yam JW; Chan LK; Ching YP; Ng IO
Liver Int; 2010 Oct; 30(9):1315-23. PubMed ID: 20629949
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform.
Sabbir MG; Wigle N; Loewen S; Gu Y; Buse C; Hicks GG; Mowat MR
BMC Biol; 2010 Mar; 8():17. PubMed ID: 20199662
[TBL] [Abstract][Full Text] [Related]
10. The human orthologue of CdGAP is a phosphoprotein and a GTPase-activating protein for Cdc42 and Rac1 but not RhoA.
Tcherkezian J; Triki I; Stenne R; Danek EI; Lamarche-Vane N
Biol Cell; 2006 Aug; 98(8):445-56. PubMed ID: 16519628
[TBL] [Abstract][Full Text] [Related]
11. Role of DLC2 and RhoA/ROCK pathway in formalin induced inflammatory pain in mice.
Wong SSC; Lee UM; Wang XM; Chung SK; Cheung CW
Neurosci Lett; 2019 Sep; 709():134379. PubMed ID: 31323253
[TBL] [Abstract][Full Text] [Related]
12. H2O2 inhibits proliferation and mediates suppression of migration via DLC1/RhoA signaling in cancer cells.
Ma L; Zhu WZ; Liu TT; Fu HL; Liu ZJ; Yang BW; Song TY; Li GR
Asian Pac J Cancer Prev; 2015; 16(4):1637-42. PubMed ID: 25743845
[TBL] [Abstract][Full Text] [Related]
13. FKBP51 regulates cell motility and invasion via RhoA signaling.
Takaoka M; Ito S; Miki Y; Nakanishi A
Cancer Sci; 2017 Mar; 108(3):380-389. PubMed ID: 28032931
[TBL] [Abstract][Full Text] [Related]
14. Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.
Zhu W; Ma L; Yang B; Zheng Z; Chai R; Liu T; Liu Z; Song T; Li F; Li G
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):589-97. PubMed ID: 26935193
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.
Nagaraja GM; Kandpal RP
Biochem Biophys Res Commun; 2004 Jan; 313(3):654-65. PubMed ID: 14697242
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
17. Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2.
Li H; Fung KL; Jin DY; Chung SS; Ching YP; Ng IO; Sze KH; Ko BC; Sun H
Proteins; 2007 Jun; 67(4):1154-66. PubMed ID: 17380510
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain.
Ng DC; Chan SF; Kok KH; Yam JW; Ching YP; Ng IO; Jin DY
FEBS Lett; 2006 Jan; 580(1):191-8. PubMed ID: 16364308
[TBL] [Abstract][Full Text] [Related]
19. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
Healy KD; Hodgson L; Kim TY; Shutes A; Maddileti S; Juliano RL; Hahn KM; Harden TK; Bang YJ; Der CJ
Mol Carcinog; 2008 May; 47(5):326-37. PubMed ID: 17932950
[TBL] [Abstract][Full Text] [Related]
20. The role of RhoA in the regulation of cell morphology and motility.
Tkach V; Bock E; Berezin V
Cell Motil Cytoskeleton; 2005 May; 61(1):21-33. PubMed ID: 15776463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
